Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Buys 55,732 Shares of Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 55,732 shares of Cosmos Health stock in a transaction that occurred on Tuesday, November 25th. The shares were purchased at an average cost of $0.63 per share, with a total value of $35,111.16. Following the purchase, the chief executive officer owned 6,383,625 shares of the company’s stock, valued at $4,021,683.75. This represents a 0.88% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Friday, November 21st, Grigorios Siokas acquired 56,080 shares of Cosmos Health stock. The stock was acquired at an average price of $0.68 per share, for a total transaction of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.62 per share, for a total transaction of $31,815.30.
• On Wednesday, November 19th, Grigorios Siokas bought 61,614 shares of Cosmos Health stock. The shares were bought at an average price of $0.65 per share, with a total value of $40,049.10.

Cosmos Health Price Performance

Shares of NASDAQ COSM traded up $0.01 during mid-day trading on Thursday, reaching $0.63. 797,226 shares of the company were exchanged, compared to its average volume of 394,947. Cosmos Health Inc. has a 52 week low of $0.28 and a 52 week high of $1.32. The company’s 50 day moving average price is $0.91 and its 200 day moving average price is $0.72. The stock has a market capitalization of $22.12 million, a PE ratio of -0.84 and a beta of 5.32. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.

Cosmos Health (NASDAQ:COSM) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. The firm had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.40 million. Sell-side analysts forecast that Cosmos Health Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on COSM. Wall Street Zen upgraded shares of Cosmos Health to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC increased its holdings in Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 225,507 shares of the company’s stock after acquiring an additional 128,776 shares during the quarter. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.